Pancreatic Cancer Research

Clinical trialPhase 1Recruiting

Trial of DFP-14927 in Advanced Solid Tumors

A Phase I Study of DFP-14927 in Patients With Advanced Solid Tumors

Outcome
Ongoing
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Start
30 September 2019
Listed end
1 June 2026
Enrollment
30 participants
Sites
2
Primary outcomes
Determine the maximum tolerated dose (MTD); Recommended Phase II Dose (RP2D); Dose-Limiting Toxicity (DLT)
Sponsor type
Industry
Results posted
No
Last update
3 March 2025

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

This is a Phase I, open-label, single-arm, dose escalation study of DFP-14927 intravenous infusion administered to patients with refractory or relapsed solid tumors.

Detailed description public domain (ClinicalTrials.gov)

This study will determine the safety and efficacy of DFP-14927 in patients with refractory or relapsed advanced solid tumors. The study will be guided by a standard "3+3"dose escalation by observing the drug-related toxicities and dose-limiting toxicities following weekly IV infusion of DFP-14927 for each 28-day cycle (4 doses per cycle). In addition, the maximum-tolerated dose and recommended Phase II dose for DFP-14927 will be determined. Furthermore, the study will determine the pharmacokinetics and bioavailability of DFP-14927 during the first cycle of treatment using the weekly dosing schedule.